Adverse Outcomes Continue In Novel Program For Malaria In Pregnancy

by Julia Samuel on  September 13, 2016 at 11:45 PM Research News
RSS Email Print This Page Comment
Font : A-A+

In sub-Saharan Africa a novel strategy to screen pregnant women for malaria with rapid diagnostic tests does not seem to lower the risk of adverse pregnancy outcomes.
Adverse Outcomes Continue In Novel Program For Malaria In Pregnancy
Adverse Outcomes Continue In Novel Program For Malaria In Pregnancy

In an open label randomized trial published in PLOS Medicine by Feiko ter Kuile, of the Liverpool School of Tropical Medicine, antimalarials were compared with treating all pregnant women with the malaria preventive sulfadoxine-pyrimethamine (SP).

During pregnancy, undetected infection with malaria parasites can lead to maternal anemia, low birthweight, and fetal loss. In areas where malaria is endemic, the World Health Organization recommends treating pregnant women with SP, but in some areas, more than 90 percent of Plasmodium parasites are resistant to SP.

In the new study, the researchers compared this standard of care to a screening approach where pregnant women are tested approximately monthly for malaria using rapid diagnostic tests and treated with a different drug, dihydroartemisinin-piperaquine (DP) only if they test positive for the parasite.

The study, which randomly assigned 1873 HIV-negative pregnant women at three sites in Malawi to receive either strategy, found that the risks of adverse birth outcomes, at 29.9 and 28.8 percent, was similar in the two groups.

However, the prevalence of malaria at delivery was higher in the rapid screening and DP group, at 48.7 percent, compared to 40.8 percent in the SP group (relative risk=1.19 [95% confidence interval 1.07-1.33], p=0.007), meaning an additional 8 out of every 100 pregnancies would be affected by malaria using this approach compared to broad prevention using SP.

Moreover, the rate of fetal loss was 2.6 percent, double the rate of 1.3 percent seen among women who took intermittent doses of SP (relative risk=2.06 [1.01-4.21], p=0.046). The current results, however, may not hold true in all areas because risk of malaria transmission varies according to location, as does parasite resistance to drugs.

In addition, the study design did not investigate the outcomes of using monthly DP for prevention without coupling it to screening.

"These results suggest that [intermittent screening and treatment with DP] may not be a suitable alternative strategy to replace [intermittent preventive therapy with SP] in settings similar to ours and may even predispose to unfavorable pregnancy outcomes in these settings," the authors say.

Source: Eurekalert

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Trimester of pregnancy Pregnancy and Exercise Home Pregnancy Test Pregnancy Malaria-water Malaria Mosquito Diseases Psychological Changes In Pregnancy Drugs in Pregnancy and Lactation Breech Presentation and Delivery 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store


News Category

News Archive